Progesterone Receptor Modulators
5 drugsAbout Progesterone Receptor
The Progesterone Receptor (PR), a member of the nuclear receptor superfamily, is a ligand-activated transcription factor that regulates gene expression in response to progesterone, influencing various physiological processes.
Genetic evidence offers moderate support for targeting PGR, with variants linked to uterine fibroid (score 0.61), abnormal blistering of the skin (0.55), and congestive heart failure (0.53); inhibition is likely beneficial. There are also 17 strong eQTL/pQTL signals (max H4: 1.00).
Five FDA-approved small molecule drugs target the progesterone receptor, including MIFEPRISTONE, MIFEPREX, KORLYM, MYFEMBREE and NUBEQA, spanning metabolic, oncology and other indications.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Healthy Participants with only 4 trials.
Progesterone Receptor Genetic Evidence Moderate
Genetic evidence provides moderate support for PGR as a drug target, with a max score of 0.61.
Moderate genetic support suggests further investigation into the causal link between PGR and disease is warranted to increase confidence.
💡 Why inhibition?
- • Loss-of-function variants reduce disease risk (OR < 1)
- • 100% directional consistency across 1 traits
- • Strong signal in musculoskeletal or connective tissue disease, genetic, familial or congenital disease, cancer or benign tumor pathways
Cross-Disease Effects
Trade-off: LowDirection of Effect
100% alignedEvidence Across Diseases
17 totalGWAS and other genetic studies link PGR to 17 diseases.
Inhibiting this target may be therapeutic
🔗 Colocalization Evidence 17 strong
max H4: 1.00eQTL/pQTL signals for PGR colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top Progesterone Receptor Drugs
Five companies have approved drugs targeting the progesterone receptor, including Bayer, EVITA SOLUTIONS, and CORCEPT THERAP.
The presence of multiple players suggests a moderately competitive landscape, requiring a differentiated approach for new entrants.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| MYFEMBREE | SUMITOMO PHARMA AM | 2021 | 3 |
| NUBEQA | Bayer | 2019 | 1 |
Progesterone Receptor Drug Modality Landscape
Modalities
Routes of Administration
Progesterone Receptor is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or PROTACs could provide a competitive advantage and expand therapeutic options.
Progesterone Receptor Clinical Trials 426 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 115 | 77 | 10 | 28 | 89% |
| Phase 2 | 112 | 45 | 23 | 44 | 66% |
| Phase 3 | 83 | 52 | 11 | 20 | 83% |
| Phase 4 | 116 | 72 | 22 | 22 | 77% |
Top Sponsors
By Modality
Top Conditions
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved Progesterone Receptor drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting Progesterone Receptor. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Progesterone Receptor Drug Approval Timeline (2000 - 2021)
The first drug was approved in 2000 (MIFEPREX), and the most recent in 2021 (MYFEMBREE), spanning 22 years.
The recent approval suggests continued interest in the target, but a slowing approval rate may indicate market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 5 companies competing
- • Market share by company
Full Drug Portfolio
- • All 5 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 5-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 327 clinical trials targeting Progesterone Receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities